Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pharma Q3 Results Preview: J&J, Roche Set The Scene

Executive Summary

Most of the big pharma companies will report their third-quarter results over the next three weeks. As usual, Johnson & Johnson and Roche will get out of the blocks early on. Scrip considers what to expect from the two front-runners, in the first of our regular financial results previews.


Related Content

Pfizer Sets The Stage For A Biosimilar Showdown Over Exclusive Contracts
Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod
J&J's Guselkumab Nears Crowded EU Psoriasis Market After CHMP OK
Pfizer Poised To PROSPER From Xtandi In Expanded Indication
Big Pharma Set To Compete For German Merck's Consumer Health Unit
COMPASS Sets Course For J&J/Bayer's Xarelto In Unexplored Indications
ALCYONE Paves Way For J&J/Genmab's Darzalex In Frontline Myeloma
Roche Lifts Outlook, Spotlights Perjeta To Drive Growth
Merck's Second-To-Market Renflexis Biosimilar Priced Below The First
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts